Abraxis BioScience (ABII)

Nucleic Acid Complementation Technology

We are pursuing the development of an engineered split-toxin platform that leads to the functional reconstitution of a cytotoxin from multiple parts under very specific conditions (for example, in cancer cells arising from known genetic anomalies or in virus-infected cells). This strategy does not require traditional high-throughput drug screening methodologies and has the added capability of being further modified to serve as a diagnostic tool for monitoring patients’ responses to therapy. This research is being pursued through DiThera, Inc. (DiThera). In December 2008, we purchased preferred stock of DiThera representing 50% of DiThera’s outstanding capital stock. DiThera is consolidated in our financial statements for the years ended December 31, 2009 and 2008.

Nucleic Acid Complementation Technology

We are pursuing the development of an engineered split-toxin platform which leads to the functional reconstitution of a cytotoxin from multiple parts under very specific conditions (for example, in cancer cells arising from known genetic anomalies or in virus-infected cells). This strategy does not require traditional high-throughput drug screening methodologies and has the added capability of being further modified to serve as a diagnostic tool for monitoring patients’ responses to therapy. This research is being pursued through Dithera, Inc. (Dithera). In December 2008, we purchased preferred stock of Dithera representing 50% of Dithera’s outstanding capital stock and were required under GAAP to consolidate Dithera in our 2008 financial statements.